Elk Creek Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Elk Creek Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,089	Closed	-$200K	–	132
2019 Q1	$200K	Sell	1,089 -448	-29%	-$82.7K	0.01%	131
2018 Q4	$255K	Sell	1,537 -2,253	-59%	-$390K	0.02%	128
2018 Q3	$730K	Hold	3,790	–	–	0.04%	125
2018 Q2	$644K	Sell	3,790 -182	-5%	-$28.2K	0.04%	128
2018 Q1	$647K	Buy	3,972 +580	+17%	+$94.7K	0.04%	131
2017 Q4	$508K	Hold	3,392	–	–	0.03%	135
2017 Q3	$516K	Buy	3,392 +272	+9%	+$40.9K	0.03%	133
2017 Q2	$402K	Hold	3,120	–	–	0.03%	136
2017 Q1	$341K	Buy	3,120 +10	+0.3%	+$880	0.02%	139
2016 Q4	$229K	Sell	3,110 -1,247	-29%	-$101K	0.02%	147
2016 Q3	$380K	Sell	4,357 -405	-9%	-$38.3K	0.03%	133
2016 Q2	$410K	Sell	4,762 -6,577	-58%	-$568K	0.03%	130
2016 Q1	$901K	Sell	11,339 -850	-7%	-$76.9K	0.07%	130
2015 Q4	$1.53M	Sell	12,189 -268	-2%	-$32.4K	0.11%	124
2015 Q3	$1.3M	Buy	12,457 +6,251	+101%	+$803K	0.1%	130
2015 Q2	$766K	Sell	6,206 -5,738	-48%	-$723K	0.07%	142
2015 Q1	$1.41M	Hold	11,944	–	–	0.15%	143
2014 Q4	$1.42M	Buy	+11,944	New	+$1.35M	0.18%	139

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Elk Creek Partners's VRTX Position: Q2 2019 in Review

Elk Creek Partners sold out of Vertex Pharmaceuticals (VRTX) in Q2 2019, closing a stake of 1,089 shares — an estimated $200K sold.

Elk Creek Partners first reported a position in VRTX in Q4 2014 and held it in 18 quarters. The position peaked at $1.53M in Q4 2015. 716 funds tracked by Wall St. Rank hold VRTX as of Q2 2019.

Elk Creek Partners reported no remaining Vertex Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Elk Creek Partners sold 1,089 Vertex Pharmaceuticals shares in Q2 2019, an estimated $200K.
Elk Creek Partners first reported a position in Vertex Pharmaceuticals in Q4 2014 and held it in 18 quarters.
Elk Creek Partners's Vertex Pharmaceuticals position peaked at $1.53M in Q4 2015.
716 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2019.

Based on Elk Creek Partners's 13F filing for Q2 2019, filed 9 Aug 2019.